Aitziber Buqu

List of Publications by Citations

55 papers	4,616 citations	23 h-index	61 g-index
61 ext. papers	6,122 ext. citations	10.8 avg, IF	5.89 L-index

#	Paper	IF	Citations
55	Immunogenic cell death in cancer and infectious disease. *Nature Reviews Immunology*, **2017**, 17, 97-111	36.5	1257
54	Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. *Cancer Cell* , **2015**, 28, 690-714	24.3	828
53	Consensus guidelines for the detection of immunogenic cell death. *OncoImmunology*, **2014**, 3, e955691	7.2	524
52	Classification of current anticancer immunotherapies. *Oncotarget*, **2014**, 5, 12472-508	3.3	301
51	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. *Cancer Cell*, **2016**, 30, 147-160	24.3	285
50	Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. *Nature Reviews Clinical Oncology*, **2020**, 17, 725-741	19.4	223
49	Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. *Nature Immunology*, **2020**, 21, 1160-1171	19.1	94
48	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. *OncoImmunology* , **2016**, 5, e1088631	7.2	81
47	Trial Watch: Peptide-based anticancer vaccines. *OncoImmunology*, **2015**, 4, e974411	7.2	81
46	Trial Watch-Oncolytic viruses and cancer therapy. *OncoImmunology*, **2016**, 5, e1117740	7.2	76
45	eIF2□phosphorylation as a biomarker of immunogenic cell death. *Seminars in Cancer Biology*, **2015**, 33, 86-92	12.7	73
44	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. *OncoImmunology*, **2015**, 4, e1008814	7.2	68
43	Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients. *OncoImmunology*, **2019**, 8, e1655964	7.2	55
42	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. *Immunological Reviews*, **2017**, 280, 165-174	11.3	52
41	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. *OncoImmunology*, **2016**, 5, e1214790	7.2	51
40	Modeling Tumor Immunology and Immunotherapy in Mice. *Trends in Cancer*, **2018**, 4, 599-601	12.5	46
39	Immunomodulation by targeted anticancer agents. *Cancer Cell*, **2021**, 39, 310-345	24.3	44

38	Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. *OncoImmunology*, **2016**, 5, e1149674	7.2	41
37	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. *Nature Communications*, **2020**, 11, 3819	17.4	41
36	The ratio of CD8/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma. *OncoImmunology*, **2016**, 5, e1218106	7.2	39
35	Trial Watch-Immunostimulation with cytokines in cancer therapy. *OncoImmunology*, **2016**, 5, e1115942	7.2	35
34	PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. *OncoImmunology*, **2020**, 9, 1721810	7.2	31
33	Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells. *Molecular Cancer*, **2012**, 11, 25	42.1	24
32	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. *OncoImmunology*, **2018**, 7, e1433982	7.2	23
31	Trial Watch: Adoptive cell transfer for oncological indications. *OncoImmunology*, **2015**, 4, e1046673	7.2	22
30	Trial watch: Naked and vectored DNA-based anticancer vaccines. *OncoImmunology*, **2015**, 4, e1026531	7.2	22
29	Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies. *Clinical and Translational Oncology*, **2014**, 16, 339-50	3.6	21
28	Anticancer effects of anti-CD47 immunotherapy. *OncoImmunology*, **2019**, 8, 1550619	7.2	19
27	Estrogen receptor 1 gene expression and its combination with estrogen receptor 2 or aromatase expression predicts survival in non-small cell lung cancer. *PLoS ONE*, **2014**, 9, e109659	3.7	18
26	Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells. *PLoS ONE*, **2013**, 8, e63338	3.7	18
25	Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. *OncoImmunology*, **2016**, 5, e1139275	7.2	17
24	Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER Breast Cancer. *Clinical Cancer Research*, **2021**, 27, 1855-1863	12.9	17
23	Apoptotic caspases cut down the immunogenicity of radiation. *OncoImmunology*, **2019**, 8, e1655364	7.2	14
22	Morphometric analysis of immunoselection against hyperploid cancer cells. *Oncotarget*, **2015**, 6, 41204-153	353	13
21	LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells. *OncoImmunology*, **2021**, 10, 1962592	7.2	12

20	Podocalyxin-like protein 1 functions as an immunomodulatory molecule in breast cancer cells. *Cancer Letters*, **2015**, 368, 26-35	9.9	10
19	Reply: Immunosuppressive cell death in cancer. *Nature Reviews Immunology*, **2017**, 17, 402	36.5	8
18	Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment.. *Nature Reviews Drug Discovery*, **2022**,	64.1	7
17	Reply: The complement system is also important in immunogenic cell death. *Nature Reviews Immunology*, **2017**, 17, 143	36.5	5
16	Methods to Detect Immunogenic Cell Death In Vivo. *Methods in Molecular Biology*, **2020**, 2055, 433-452	1.4	4
15	Possible mechanisms of cancer prevention by nicotinamide. *British Journal of Pharmacology*, **2021**, 178, 2034-2040	8.6	3
14	Prevention of breast cancer by RANKL/RANK blockade. *Cell Research*, **2016**, 26, 751-2	24.7	2
13	Immunofluorescence microscopy-based assessment of cytosolic DNA accumulation in mammalian cells. *STAR Protocols*, **2021**, 2, 100488	1.4	2
12	Monitoring abscopal responses to radiation in mice. *Methods in Enzymology*, **2020**, 635, 111-125	1.7	2
11	Cytofluorometric assessment of cell cycle progression in irradiated cells. *Methods in Cell Biology*, **2022**,	1.8	1
10	Ketosis versus carbotoxicity - metabolism determines the outcome of cancer immunotherapy. *Molecular and Cellular Oncology*, **2021**, 8, 1868266	1.2	1
9	Targeting Serine in Cancer: Is Two Better Than One?. *Trends in Cancer*, **2021**, 7, 668-670	12.5	1
8	MPA/DMBA-driven mammary carcinomas. *Methods in Cell Biology*, **2021**, 163, 1-19	1.8	0
7	Final results of a phase II study of bevacizumab, cisplatin and pemetrexed as first-line therapy for patients with advanced non squamous non small cell lung cancer.. *Journal of Clinical Oncology*, **2015**, 33, e19036-e19036	2.2	
6	Final Results of a Phase II Study of Bevacizumab, Cisplatin and Pemetrexed as First-Line Therapy for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer. *Journal of Cancer Therapy*, **2016**, 07, 455-463	0.2	
5	Elderly patients and ovarian epithelial cancer (OEC) or primary peritoneal carcinoma (PPC): A retrospective analysis.. *Journal of Clinical Oncology*, **2013**, 31, e20718-e20718	2.2	
4	Preoperative chemoradiotherapy (QT-RT) with capecitabine and oxaliplatin (CAPOX) or capecitabine alone (CAP) in patients (PTS) with locally advanced rectal cancer (LARC).. *Journal of Clinical Oncology*, **2013**, 31, e14712-e14712	2.2	
3	Today's Special on the Anticancer Menu: Immunomodulation by Antifolates. *Clinical Cancer Research*, **2019**, 25, 6890-6892	12.9	

List of Publications

2	Cytofluorometric assessment of acute cell death responses driven by radiation therapy. *Methods in Cell Biology*, **2022**,	1.8
1	RT-PCR-assisted quantification of type I IFN responses in irradiated cancer cells. *Methods in Cell Biology*, **2022**,	1.8